Both tumor volume and weight measurements taken 30-day post-injection clearly showed that genetic inhibition of JMJD2B significantly impaired in vivo tumor growth of HCT116 p53+/+ cells relative to control group (Figure 7G and Supplementary Figure S6E), while having a modest, not statistically significant, impact on the growth of HCT116 p53−/− cells (Figure 7H and Supplementary Figure S6F). Here, TP53 is linked to neoplasm.